Monopoly 2.0 - dealing with dominance in today's digital economy and life-sciences sectors
Stockholm
11 - 13 June 2020
In June 2020 Stockholm will host the AIJA conference titled ‘Monopoly: 2.0, dealing with dominance in today's digital economy and life-sciences sectors'. This joint seminar organised by the AIJA Antitrust Commission in cooperation with the AIJA Healthcare & Life-Sciences Commission will focus on ‘dominance’ and its consequences, rethinking the concept and the definition of market power in a global and digital economy and in markets that are rapidly changing, in particular also addressing the life-sciences sector.
With great power comes great responsibility. This century old adagium is very much alive in antitrust policy and enforcement. The most recent developments will be tackled, including antitrust enforcers' approach to BigTech across the globe, platform-to-business relationships, the interplay between competition laws and privacy regulation, the rise of eco-systems as well as merger control developments.
The healthcare and life sciences break-out sessions will compare how important issues related to purchases of pharmaceutical products are handled around the world and use this unique opportunity to assess how competition law affects healthcare and life sciences.
Join us in Stockholm to learn and debate these trending topics! The academic programme will be complemented by a rich social schedule, with a chance to see Stockholm from the seaside and excellent opportunities to meet and see old and new friends.
AIJA Commissions
- Antitrust
- Healthcare and Life Sciences
Programme complet
Antitrust Track
Thursday 11 June 2020
18:00 » 19:00Registration at the Clarion Hotel Sign
Address: Östra Järnvägsgatan 35, 111 20 Stockholm, Sweden19:00 » 20:30Welcome cocktails at the Clarion Hotel Sign
Address: Östra Järnvägsgatan 35, 111 20 Stockholm, Sweden
21:00 » 23:00Optional dinner23:00Optional bar and clubbing
Friday 12 June 2020
08:00 » 09:00Registration at the Clarion Hotel Sign
Address: Östra Järnvägsgatan 35, 111 20 Stockholm, Sweden09:00 » 09:30Introduction to the Seminar by AIJA President09:30 » 10:30Seminar session 1: Monopoly 2.0 - Introduction to the game
Introduction: Academic background and introduction to the main challenges in rapidly evolving markets
Moderator:
Sofia Falkner, Advokatfirman Hammarskiöld (Sweden)10:30 » 11:00Coffee break11:00 » 12:30Seminar session 2: Rethinking dominance and the concept of abuse
- Is the current legal framework to take into account new factors when assessing market power/ whether a monopoly exists? Can we still apply traditional methods for the definition of markets that are rapidly changing?
- What behaviour of a company with a dominant position may constitute an abuse of a dominant position?
Moderator:
Sebastian Janka, Luther Rechtsanwaltsgesellschaft mbH12:30 » 13:30Lunch13:30 » 15:00Seminar session 3: Life Sciences – Dominance and its abuse (Article 102) in the moment of patent expiration
- Narrow definition of markets for pharmaceutical products – is every innovative producer a dominant?
- Pay-for-delay abuse of dominance
- Market definition and dominance contra innovation and pipeline products
- Practical aspects of producers of dominant drugs in the moment of patent expiration
Moderator:
Martin Abraham, Abraham & Partneři15:00 » 15:30Coffee break15:30 » 17:00Seminar session 4.1: Procedure, sanctions and remedies
Moderator:
Johanna Svantesson, DLA Piper20:00Dinner23:00Optional bar and clubbing
Saturday 13 June 2020
09:30 » 11:00Seminar session 5.1: Regulating BigTech
- US investigations
- EU developments
- Approach in Asia
Moderator:
Johan Wahlbom, Vinge11:00 » 11:30Coffee break11:30 » 13:00Seminar session 6.1: Data and platform economy
- “New” competitive problems regarding platforms as two-sided markets
- Data protection as a competitive concern for internet “giants”?: investigations into platforms such as Facebook
- Algorithms and Competition (e.g. study of German FCO and French Autorité de la Concurrence)
- Network effects 2.0: Mergers of platforms (e.g. Dating & Real Estate)
Responsible contact person:
Beatrice Stange, Heuking Kühn Lüer Wojtek13:00 » 14:00Lunch14:30 » 18:30Optional afternoon social program20:30Optional dinner
Healthcare and Life Sciences Track
Thursday 11 June 2020
18:00 » 19:00Registration at the Clarion Hotel Sign
Address: Östra Järnvägsgatan 35, 111 20 Stockholm, Sweden19:00 » 20:30Welcome cocktails at the Clarion Hotel Sign
Address: Östra Järnvägsgatan 35, 111 20 Stockholm, Sweden21:00 » 23:00Optional dinner23:00Optional bar and clubbing
Friday 12 June 2020
08:00 » 09:00Registration at the Clarion Hotel Sign
Address: Östra Järnvägsgatan 35, 111 20 Stockholm, Sweden09:00 » 09:30Introduction to the Seminar by AIJA President09:30 » 10:30Seminar session 1: Monopoly 2.0 - Introduction to the game
Introduction: Academic background and introduction to the main challenges in rapidly evolving markets
Moderator:
Sofia Falkner, Advokatfirman Hammarskiöld (Sweden)10:30 » 11:00Coffee break11:00 » 12:30Seminar session 2: Rethinking dominance and the concept of abuse
- Is the current legal framework to take into account new factors when assessing market power/ whether a monopoly exists? Can we still apply traditional methods for the definition of markets that are rapidly changing?
- What behaviour of a company with a dominant position may constitute an abuse of a dominant position?
Moderator:
Sebastian Janka, Luther Rechtsanwaltsgesellschaft mbH12:30 » 13:30Lunch13:30 » 15:00Seminar session 3: Life Sciences – Dominance and its abuse (Article 102) in the moment of patent expiration
- Narrow definition of markets for pharmaceutical products – is every innovative producer a dominant?
- Pay-for-delay abuse of dominance
- Market definition and dominance contra innovation and pipeline products
- Practical aspects of producers of dominant drugs in the moment of patent expiration
Moderator:
Martin Abraham, Abraham & Partneři15:30 » 17:00Seminar session 4.2: Practical implications on the Medical Device Regulation (MDR)
- Current status – what is in place and what is missing?
- Update from the authorities
- The death of small med-tech companies and start-ups?
- How to mitigate risk in the yet uncertain fields
- Brexit
Responsible contact person/Moderator:
Siri Mårtensson Hjälmberg, Morris Law20:00Dinner23:00Optional bar and clubbing
Saturday 13 June 2020
09:30 » 11:00Seminar session 5.2: Purchasing pharmaceutical products – introductory session
I. Patient’s legal right to free healthcare vs public interest on financial stability of the healthcare system (in the world of new super expensive pharmaceutical products)
a) Is there a limit on costs per patient, i.e. on his legal right to free healthcare?
b) Who decides?
c) Does the patient have a judicial recourse?
d) Do patients have access to pharmaceutical products without set reimbursement and/or maximal price? Under what circumstances?
II. Interventions of national drugs authorities into prices of pharmaceutical products - are pharmaceutical companies obliged to sell below their market prices, hurting their external pricing reference?
Responsible contact person:
Tímea Halkó, Gedeon Richter Plc.11:00 » 11:30Coffee break11:30 » 13:00Seminar session 6.2: Purchasing pharmaceutical products – interactive session- mock constitutional trial
Patient in need of super expensive cure suing his public sick-fund13:00 » 14:00Lunch14:30 » 18:00Optional afternoon social program20:30Optional dinner
Sponsors
PLATINUM
GOLD
Comité organisateur
Martin ABRAHAM
Abraham & Partneri, advokatni kancelar s.r.o. (CZECH REPUBLIC)
Sofia FALKNER
Advokatfirman Hammarskiöld & Co AB (SWEDEN)
Sophie GILLIAM
DLA Piper Nederland N.V. (NETHERLANDS)
Tímea HALKO
Gedeon Richter Plc. (HUNGARY)
Siri MåRTENSSON
Advokatfirman Morris AB (SWEDEN)
Boris OSTROUKHOV
ALRUD Law Firm (RUSSIAN FEDERATION)
Beatrice STANGE
Heuking Kühn Lüer Wojtek PartmbB (GERMANY)
Johanna SVANTESSON
Advokatfirma DLA Piper Sweden KB (SWEDEN)
Ewan TOWNSEND
Arnold & Porter (UNITED KINGDOM)
Johan WAHLBOM
Advokatfirman Vinge KB (SWEDEN)
Programme complet
Antitrust Track
Thursday 11 June 2020
Address: Östra Järnvägsgatan 35, 111 20 Stockholm, Sweden
Address: Östra Järnvägsgatan 35, 111 20 Stockholm, Sweden
Friday 12 June 2020
Address: Östra Järnvägsgatan 35, 111 20 Stockholm, Sweden
Introduction: Academic background and introduction to the main challenges in rapidly evolving markets
Moderator:
Sofia Falkner, Advokatfirman Hammarskiöld (Sweden)
- Is the current legal framework to take into account new factors when assessing market power/ whether a monopoly exists? Can we still apply traditional methods for the definition of markets that are rapidly changing?
- What behaviour of a company with a dominant position may constitute an abuse of a dominant position?
Sebastian Janka, Luther Rechtsanwaltsgesellschaft mbH
- Narrow definition of markets for pharmaceutical products – is every innovative producer a dominant?
- Pay-for-delay abuse of dominance
- Market definition and dominance contra innovation and pipeline products
- Practical aspects of producers of dominant drugs in the moment of patent expiration
Martin Abraham, Abraham & Partneři
Moderator:
Johanna Svantesson, DLA Piper
Saturday 13 June 2020
- US investigations
- EU developments
- Approach in Asia
Johan Wahlbom, Vinge
- “New” competitive problems regarding platforms as two-sided markets
- Data protection as a competitive concern for internet “giants”?: investigations into platforms such as Facebook
- Algorithms and Competition (e.g. study of German FCO and French Autorité de la Concurrence)
- Network effects 2.0: Mergers of platforms (e.g. Dating & Real Estate)
Beatrice Stange, Heuking Kühn Lüer Wojtek
Healthcare and Life Sciences Track
Thursday 11 June 2020
Address: Östra Järnvägsgatan 35, 111 20 Stockholm, Sweden
Address: Östra Järnvägsgatan 35, 111 20 Stockholm, Sweden
Friday 12 June 2020
Address: Östra Järnvägsgatan 35, 111 20 Stockholm, Sweden
Introduction: Academic background and introduction to the main challenges in rapidly evolving markets
Moderator:
Sofia Falkner, Advokatfirman Hammarskiöld (Sweden)
- Is the current legal framework to take into account new factors when assessing market power/ whether a monopoly exists? Can we still apply traditional methods for the definition of markets that are rapidly changing?
- What behaviour of a company with a dominant position may constitute an abuse of a dominant position?
Sebastian Janka, Luther Rechtsanwaltsgesellschaft mbH
- Narrow definition of markets for pharmaceutical products – is every innovative producer a dominant?
- Pay-for-delay abuse of dominance
- Market definition and dominance contra innovation and pipeline products
- Practical aspects of producers of dominant drugs in the moment of patent expiration
Martin Abraham, Abraham & Partneři
- Current status – what is in place and what is missing?
- Update from the authorities
- The death of small med-tech companies and start-ups?
- How to mitigate risk in the yet uncertain fields
- Brexit
Siri Mårtensson Hjälmberg, Morris Law
Saturday 13 June 2020
I. Patient’s legal right to free healthcare vs public interest on financial stability of the healthcare system (in the world of new super expensive pharmaceutical products)
Responsible contact person:
Tímea Halkó, Gedeon Richter Plc.
Patient in need of super expensive cure suing his public sick-fund
Sponsors
PLATINUM
GOLD
Comité organisateur
Martin ABRAHAM
Abraham & Partneri, advokatni kancelar s.r.o. (CZECH REPUBLIC)
Sofia FALKNER
Advokatfirman Hammarskiöld & Co AB (SWEDEN)
Sophie GILLIAM
DLA Piper Nederland N.V. (NETHERLANDS)
Tímea HALKO
Gedeon Richter Plc. (HUNGARY)
Siri MåRTENSSON
Advokatfirman Morris AB (SWEDEN)
Boris OSTROUKHOV
ALRUD Law Firm (RUSSIAN FEDERATION)
Beatrice STANGE
Heuking Kühn Lüer Wojtek PartmbB (GERMANY)
Johanna SVANTESSON
Advokatfirma DLA Piper Sweden KB (SWEDEN)
Ewan TOWNSEND
Arnold & Porter (UNITED KINGDOM)
Johan WAHLBOM
Advokatfirman Vinge KB (SWEDEN)
